PDF) New onset diabetes after nivolumab treatment
Immune checkpoint inhibitors and diabetes: Mechanisms and predictors - ScienceDirect
Frontiers | Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management
Diagnostik und Management endokriner Nebenwirkungen von Immuncheckpoint-Inhibitoren
Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes - Quandt - 2020 - Clinical & Experimental Immunology - Wiley Online Library
PDF) Immuntherapie-induzierter Diabetes mellitus Typ 1
Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus? | RCP Journals
Acute‐onset type 1 diabetes mellitus caused by nivolumab in a patient with advanced pulmonary adenocarcinoma,Journal of Diabetes Investigation - X-MOL
Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab
Sum of diameters of all target lesions during administration of... | Download Scientific Diagram
Nivolumab plus Cabozantinib verbessert PFS, OS und Lebensqualität - Onkologie - Universimed - Medizin im Fokus
A Rare Case of Severe Diabetic Ketoacidosis in a Patient With Metastatic Renal Cell Carcinoma Being Treated With Nivolumab
Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab
Diabetic ketoacidosis following immunotherapy for lung cancer | Tidsskrift for Den norske legeforening
Nivolumab: targeting PD-1 to bolster antitumor immunity | Future Oncology
Hyperosmolar Hyperglycaemic State and Diabetic Ketoacidosis in Nivolumab-Induced Insulin-Dependent Diabetes Mellitus - CNR Solar
The clinical course of multiple lines of chemotherapy and nivolumab | Download Scientific Diagram
American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach - Endocrine Practice
Nivolumab-induced acute-onset type 1 diabetes mellitus as an immune-related adverse event: A case report - Yukihisa Hatakeyama, Hisashi Ohnishi, Kentaro Suda, Kayoko Okamura, Temiko Shimada, Sho Yoshimura, 2019
Nivolumab - Anwendung, Wirkung, Nebenwirkungen | Gelbe Liste
